Loading...
Loading...
Teva Pharmaceutical Industries Ltd.
TEVA announced today
the approval by the Japanese Ministry of Health, Labour and Welfare
(MHLW) of once-daily COPAXONE® (glatiramer acetate injection)
20mg injection for the prevention of relapse of multiple sclerosis . The
product will be commercialized in Japan by Takeda Pharmaceutical Company
Limited (Takeda).
In Japan, glatiramer acetate was developed as an Unapproved New Drug by
Teva Pharmaceutical K.K., a wholly owned subsidiary of Teva, at the
request of the MHLW. In March, 2013, Takeda and Teva signed an agreement
in which Teva granted Takeda the right to commercialize COPAXONE®
in Japan.
"Strengthening our offering of specialty medicines in Japan is an
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in